Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

AMT reaches another milestone in the official marketing authorisation process for Glybera

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, has reached another important milestone in the official marketing authorisation process for its lead product Glybera(R), AMT's proprietary product for lipoprotein lipase deficiency (LPLD).

25 Jan 2010

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

Besides LDL, Lp(a) can also increase risk for heart disease

LDL isn't the only "bad boy" when it comes to cholesterol. According to a new study, a lipoprotein in the bloodstream called Lp(a) — pronounced "LP little A" — can be labeled "bad cholesterol."

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

Down syndrome and Alzheimer's disease are the same

Nearly 20 years ago Huntington Potter kicked up a storm of controversy with the idea that Down syndrome and Alzheimer's were the same disease. Now the evidence is in: He was right.

18 Jan 2010

Research suggests variation of CETP gene is linked to lowered risk of dementia and AD

Preliminary research suggests that variation of a gene for a plasma protein is associated with slower age-related memory decline and a lower risk of dementia and Alzheimer disease (AD), according to a study in the January 13 issue of JAMA.

13 Jan 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

SpectraCell Laboratories agrees to become Aetna's contracted in-network provider

SpectraCell Laboratories announced today that it has agreed with Aetna Health, one of the nation's largest health insurers, to become a contracted in-network provider. The contract provides coverage by Aetna of SpectraCell's micronutrient testing, as well as other advanced tests offered by the company.

7 Jan 2010

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.

30 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Niacin may not be beneficial for type 2 diabetic patients

High-density lipoprotein (HDL), known as "good" cholesterol, isn't as protective for people with type 2 diabetes, according to research reported in Circulation: Journal of the American Heart Association.

22 Dec 2009

Pistachios can decrease inflammation and cardiovascular disease

New research published online, December 10, 2009 indicates that bioactive compounds in pistachios, and molecules present in pistachios, have anti-inflammatory properties.

17 Dec 2009

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

Myrrh resin may have cholesterol-lowering properties

Laboratory experiments suggest that the resin of certain trees of the Middle East, known commonly as the "myrrh" of the Christmas story, may have cholesterol-lowering properties.

14 Dec 2009

Special issue focuses on cardiovascular disease prevention and outcomes

Emerging research on cardiovascular risk factors and treatment effects are helping clinicians gain a better understanding of which patients are most likely to benefit from close monitoring, lifestyle changes and/or additional therapeutic interventions.

14 Dec 2009

Whole genome analysis identifies 43 genetic loci contributing to lipoprotein metabolism

Using highly precise measurements of plasma lipoprotein concentrations determined by nuclear magnetic resonance spectroscopy (NMR), researchers led by Daniel Chasman at Brigham and Women's Hospital and Harvard Medical School in Boston, MA, the Framingham Heart Study in Framingham, and the PROCARDIS consortium in Stockholm, Sweden and Oxford, England performed genetic association analysis across the whole genome among 17,296 women of European ancestry from the Women's Genome Health Study.

21 Nov 2009

High blood pressure: A major risk factor for stroke and heart disease

Today, Jamieson Laboratories, in partnership with the Victorian Order of Nurses (VON), is holding a one day Blood Pressure Blitz in Toronto's underground PATH system in an effort to educate consumers about the number one risk factor for stroke and a major risk factor of heart disease.

20 Nov 2009

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

18 Nov 2009

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Data released today at the American Heart Association (AHA) Scientific Sessions 2009 define the increased risk of heart attacks and cardiovascular disease in patients with low levels of HDL-C (known as "good cholesterol"). The data also determine that statins are unable to significantly impact the heart attack or cardiovascular disease risks associated with low HDL-C.

18 Nov 2009

Lipoprotein News and Research

Further Reading

AMT reaches another milestone in the official marketing authorisation process for Glybera

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Besides LDL, Lp(a) can also increase risk for heart disease

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Down syndrome and Alzheimer's disease are the same

Research suggests variation of CETP gene is linked to lowered risk of dementia and AD

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

SpectraCell Laboratories agrees to become Aetna's contracted in-network provider

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Niacin may not be beneficial for type 2 diabetic patients

Pistachios can decrease inflammation and cardiovascular disease

Low plasma CETP activity associated with increased risk of heart disease, says study

Myrrh resin may have cholesterol-lowering properties

Special issue focuses on cardiovascular disease prevention and outcomes

Whole genome analysis identifies 43 genetic loci contributing to lipoprotein metabolism

High blood pressure: A major risk factor for stroke and heart disease

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

CRESTOR reduces major cardiovascular events in women by 46%

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News